Uso de anticorpos monoclonais na prevenção de infecções por vírus sincicial respiratório em prematuros: efeitos sobre hospitalização e desfechos clínicos.
Revista ft · 21.05.2026 · 30 (158) · 01-29
DOI: 10.69849/axbtqp49 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 21.05.2026. Verfasst von Rayanne Reinaldo Moreira und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections in infants, presenting high morbidity in premature infants. Traditional prevention was based on palivizumab; however, restrictive changes in the American Academy of Pediatrics guidelines in 2014 and the recent introduction of nirsevimab have reconfigured the global prophylactic landscape.
Objectives
To analyze the impact of changes in RSV prophylaxis guidelines and to evaluate the efficacy, safety, and cost-effectiveness of new monoclonal antibodies, specifically nirsevimab, in reducing hospitalizations and severe outcomes in premature infants. Methodology: This is an integrative literature review conducted in the BVS and PubMed databases. The initial search retrieved 614 records, from which, after rigorous methodological refinement and removal of duplicates, 37 articles were selected to compose the final analytical corpus. Results and discussion: the current scenario is marked by high hospitalization rates in late preterm infants (29-34 weeks), a fact that generates an economic paradox due to the high cost of intensive care. In contrast, nirsevimab emerges as a robust alternative, with efficacy greater than 80% in preventing hospitalizations with a single dose. In addition, analyses of different global sociodemographic contexts confirm the effectiveness of universal immunization, drastically reducing the hospital burden and the need for ventilatory support. Furthermore, cost-effectiveness analyses indicate that the transition to universal strategies is economically viable, especially by mitigating highly complex operational costs.
Conclusion
The transition to universal immunoprophylaxis strategies with nirsevimab and maternal vaccination promises to overcome the logistical limitations and epidemiological burden of the palivizumab restriction; however, its real impact in Brazil depends on adaptation to local seasonality, mitigation of socio-assistance determinants, and effective integration between different levels of health care.
Zitieren
APA
Moreira, R. R., Azevedo, A. L. D., Santana, E. A. D., Bahia, M. L. M., Passos, T. P. G., & Tourinho, L. D. O. S. (2026). Uso de anticorpos monoclonais na prevenção de infecções por vírus sincicial respiratório em prematuros: efeitos sobre hospitalização e desfechos clínicos. Revista ft, 30(158), 01-29. https://doi.org/10.69849/axbtqp49
Vancouver
Moreira RR, Azevedo ALD, Santana EAD, Bahia MLM, Passos TPG, Tourinho LDOS. Uso de anticorpos monoclonais na prevenção de infecções por vírus sincicial respiratório em prematuros: efeitos sobre hospitalização e desfechos clínicos. Revista ft. 2026;30(158):01-29. doi:10.69849/axbtqp49
BibTeX
@article{Moreira2026,
author = {Moreira, Rayanne Reinaldo and Azevedo, Ana Laura Dias and Santana, Emille Alves de and Bahia, Matheus Leite Mamedio and Passos, Tobias Pecorelli Gama and Tourinho, Luciano de Oliveira Souza},
title = {Uso de anticorpos monoclonais na prevenção de infecções por vírus sincicial respiratório em prematuros: efeitos sobre hospitalização e desfechos clínicos},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {158},
pages = {01--29},
doi = {10.69849/axbtqp49}
}
EUVIMED